DSM Biomedical today announced the appointments of Mr. Donato Di Biase as Business Director Drug Delivery and Regenerative Medicine and Dr. Julian Adams as Intellectual Asset Manager.

Mr. Di Biase has a background in Biology and Medicine. He held various commercial and operation management roles in companies active in biomedical materials and medical diagnostics. Before joining DSM, Mr. Di Biase was Managing Director/COO at Hemoteq GmbH, a leading provider of surface modification solutions for medical devices. At DSM Biomedical Mr Di Biase will be responsible for DSM’s efforts to develop materials solutions for drug delivery and regenerative medicine.

Dr. Adams previously worked for Smith & Nephew, a global medical devices company, where he held various positions. In his last role he acted as patent attorney for the Enabling Technologies Department and the Endoscopy business. Dr Adams holds a Bachelor of Science Degree in Applied Biology from the University of Cardiff and a PhD in the Cell Kinetics of Wound Healing from the University of Manchester. At DSM Biomedical Dr. Adams will be responsible for strategy development and its implementation in intellectual property to insure the company captures the most value from this area.

Steve Hartig, Vice President Biomedical: “A key to our success in the future is combining the strengths of DSM’s technologies and products with high level external expertise and ability from the Medical Device and Biomedical Material industries. Drug delivery is a focus area for our future growth and Donato’s backgrounds and strengths will allow us to accelerate our efforts. I am also very pleased with the appointment of Julian Adams. In all biomedical activities, intellectual capital is critical and we are confident that Julian will bring us significant value in this area.”

About DSM Biomedical
To meet the upcoming needs of the medical and biotech industries, DSM Biomedical builds on the expertise and strengths of DSM in polymers, coating technology, materials science and life sciences. DSM’s current biomedical portfolio includes hydrophilic coating technology for catheters, guidewires and stent delivery systems and Dyneema Purity®, a highly purified range of products which have been developed specifically for use in medical applications, such as orthopedic implants, where maximum strength and minimum weight are required. Furthermore DSM Biomedical is focusing on developing materials and systems around implantable devices for the musculoskeletal and vascular systems and drug delivery devices in musculoskeletal, vascular and ophthalmic application